Betta Pharmaceuticals Co.Ltd(300558)
Financial statement report of 2021
Betta Pharmaceuticals Co.Ltd(300558) (hereinafter referred to as “the company”) has completed the financial settlement in 2021. The financial accounting report is prepared in accordance with the accounting standards for business enterprises. Lixin Certified Public Accountants (special general partnership) has issued the standard unqualified audit report “Xin Kuai Shi Bao Zi [2022] No. zf10203”. Now the relevant financial settlement is briefly reported as follows. For details, please refer to the financial report in the annual report of the company. 1、 Operating results (consolidated statement data, the same below)
In 2021, the operating revenue increased by 20.08% over the same period of the previous year, and the net profit attributable to the shareholders of the listed company decreased by 36.83% over the same period of the previous year. See the following table for main data:
Unit: 10000 yuan
Year on year increase / decrease ratio of current year’s amount and last year’s amount (%)
Operating income 22458556187026633755893 20.08
Total profit 38992756666623 -2767348 -41.51
Net profit 37956076010857 -2215250 -36.85
Net profit attributable to shareholders of listed company 38306786063606 -2232928 -36.83
Net profit attributable to shareholders of listed company after deducting non recurring profit and loss 34568023339289117513 3.52 II. Items and amount of non recurring profit and loss
Unit: 10000 yuan
Year on year increase or decrease of the current year’s amount and the previous year’s amount of the project
Gains and losses on disposal of non current assets 3.38 -169.72 173.10
Ultra vires approval, or no formal approval document, or occasional tax return and reduction
The government subsidies included in the current profits and losses (closely related to the business of the enterprise, except the government subsidies enjoyed in accordance with the national unified standard of 321000271000 500.00 quota or quota) the investment cost of the subsidiary, associated enterprise and joint venture obtained by the enterprise is less than the income from the fair value of the identifiable net assets of the investee when the investment is obtained, except for the effective hedging business related to the normal business of the company
The fair value of trading financial assets and trading financial liabilities changes to 164691 312.03133488 profit and loss, as well as the investment income obtained from the disposal of trading financial assets, trading financial liabilities and available for sale financial assets
Other non operating income and expenses other than the above -508.86 -133090 822.04
Other profit and loss items that meet the definition of non recurring profit and loss 2899097 -2899097
Income tax impact amount -610.27 -326832265805
Influence amount of minority shareholders’ equity (after tax) -2.40 -0.88 -1.52
Total 373876, 2724317 – 2350441
3、 Assets, liabilities and owner’s equity 1. Assets
As of December 31, 2021, the total assets of the company were 62714321 million yuan, an increase of 19.92% over the balance at the end of the previous year, including 16539357 million yuan of current assets and 46174964 million yuan of non current assets. (1) Current assets of the company
The balance at the end of 2021 was 1653935700 yuan, a decrease of 10.49% over the balance at the end of the previous year. The main data are shown in the table below:
Unit: 10000 yuan
Year on year increase or decrease ratio of current assets project from December 31, 2021 to December 31, 2020 (%)
Monetary capital 791989613459446 -5539550 -41.16
Trading financial assets 20100552010055
Notes receivable 444.85 444.85
Accounts receivable 16893225261311163191 221.08
Advance payment 305625149324156301 104.67
Other receivables 407528 680.89339439 498.52
Inventory 293321718859391047278 55.53
Other current assets 12292282389730 -1160502 -48.56
Total current assets 1653935718478659 -1939302 -10.49
A. The ending balance of monetary capital decreased by 41.16% compared with that at the end of the previous year, mainly because the breakeven bank financial products measured at fair value during the reporting period were included in the accounting of trading financial assets; B. The ending balance of accounts receivable increased by 221.08% compared with that at the end of the previous year, mainly due to the increase of accounts receivable from new drug sales at the end of the reporting period, and more than 99% of the accounts have been collected as of the disclosure date of this report; C. The ending balance of prepayments increased by 104.67% compared with that at the end of the previous year, mainly due to the increase of prepayments for materials at the end of the reporting period;
D. The ending balance of other receivables increased by 498.52% compared with that at the end of the previous year, mainly due to the increase of individual taxes receivable and paid for the exercise of employee equity incentive at the end of the reporting period; E. The ending balance of inventory increased by 55.53% compared with that at the end of the previous year, mainly due to the increase in production and preparation due to the expected increase in sales volume due to the entry of products into medical insurance and the listing of new products during the reporting period; Increase of R & D materials; F. The ending balance of other current assets decreased by 48.56% compared with that at the end of the previous year, mainly due to the due recovery of Principal Guaranteed bank financial products measured at amortized cost during the reporting period.
(2) Non current assets of the company
The balance of non current assets at the end of 2021 was 46174964 million yuan, an increase of 36.54% over the balance at the end of the previous year. The main data are shown in the table below:
Unit: 10000 yuan
Year on year increase or decrease ratio of non current assets project from December 31, 2021 to December 31, 2020 (%)
Long term equity investment 949.38 949.38
Other equity investment instruments
Investment real estate 365071369850 -47.79 -1.29
Fixed assets 67945467126010 -331464 -4.65
Construction in progress 63966816311845765497 913.44
Right to use assets 118689
Intangible assets 11828614 Shanghai Shuixing Home Textile Co.Ltd(603365) 85794956 96.04
Development expenditure 1251607311714438801635 6.84
Goodwill 4135840
Deferred income tax assets 550621552232 -16.11 -0.29
Other non current assets 109.41508019 -497078 -97.85
Total non current assets 461749643381671712358247 36.54
A. The ending balance of construction in progress increased by 913.44% compared with that at the end of the previous year, mainly due to the increase in investment in DreamWorks phase II project, Shengzhou innovative drug industrialization base project and other projects during the reporting period; B. The ending balance of intangible assets increased by 96.04% compared with that at the end of the previous year, mainly due to the purchase of overseas interests of mrx2843 project and the transfer of new drug certificate obtained by beiantin project into intangible assets accounting during the reporting period; C. The ending balance of other non current assets decreased by 97.85% compared with that at the end of the previous year, mainly due to the transfer of land prepayment into intangible assets accounting during the reporting period. 2. Liabilities
As of December 31, 2021, the total liabilities of the company are 15856424 million yuan, including current liabilities of 8888593 million yuan and non current liabilities of 6967831 million yuan. The total liabilities increased by 46.10% over the balance at the end of the previous year. The main data are shown in the table below:
Unit: 10000 yuan
Year on year increase / decrease ratio of liability items from December 31, 2021 to December 31, 2020 (%)
Trading financial liabilities 1 Ping An Bank Co.Ltd(000001) 00000
Accounts payable 431187311362373175636 279.49
Advance payment 58.69 148.22 -89.53 -60.40
Contract liabilities 9.89, 126.61 -116.72 -92.19
Payroll payable 13701211171122 1
